Nevertheless, expression of TF in the context of hemophilia would not be deemed problematic, as the TF : FVIIa complex of the extrinsic pathway initiates blood coagulation by activating both FX and FIX, and there are currently products on the market that use recombinant activated factor VII (rFVIIa) to treat and/or prevent hemorrhagic complications in persons with hemophilia with inhibitors (43). This evidence concerns the gene F7 and hemophilia.